BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical ...

today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in ...

today announced that the company will present a poster highlighting the preclinical activity of epetraborole against M. abscessus on Thursday, May 29, 2025 at the Nontuberculous Mycobacteria ...

Vadadustat Combination with Ferric Citrate, Compared to Either Agent Alone, Protects Against Inflammation-Induced Anaemia and Anaemia-Induced by Chronic Kidney DiseaseE-Poster No. 2908 Real-World ...

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation ... presented in a poster entitled ...

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered ...

The poster highlights the work of researchers from the Princess Máxima Center for Pediatric Oncology (Utrecht, the Netherlands), the Hopp Children’s Cancer Center Heidelberg (KiTZ) (Heidelberg ...

today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in ...

Poster Presentation (213/3544): Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment Date/Time ...

UFC 317 is right around the corner, and the promotion has done its due diligence in putting together a poster people care about, literally. Especially considering the two title fights at the top ...